FDA to Review Roflumilast Foam for Seborrheic Dermatitis FDA to Review Roflumilast Foam for Seborrheic Dermatitis
If approved, the once-daily foam would be the first topical drug with a new mechanism of action for seborrheic dermatitis in more than two decades.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 19, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Atopic Dermatitis Highlights From AAD 2023 Atopic Dermatitis Highlights From AAD 2023
The safety of abrocitinib, data on IL-22 inhibition, and the link between atopic dermatitis (AD) and inflammatory bowel disease top the AD highlights from AAD 2023, as reported by Dr Joel Gelfand.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults
Review evidence from the latest clinical trials of tralokinumab, a new systemic interleukin-13 inhibitor for moderate-to-severe atopic dermatitis.Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 3, 2023 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
FDA Approves Drug for Cats With Allergic Skin Disease
FRIDAY, March 31, 2023 -- Cats constantly licking and chewing because of a skin condition called feline allergic dermatitis may benefit from a new generic treatment approved by the U.S. Food and Drug Administration.
The FDA approved Modulis for Cats... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 31, 2023 Category: General Medicine Source Type: news
FDA Approves Drug, Modulis, for Cats With Allergic Skin Disease
FRIDAY, March 31, 2023 -- Cats constantly licking and chewing because of a skin condition called feline allergic dermatitis may benefit from a new generic treatment approved by the U.S. Food and Drug Administration.
The FDA approved Modulis for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 31, 2023 Category: General Medicine Source Type: news
'Enhanced' Eczema Treatment Cut Food Allergy Risk, but at What Cost?
(MedPage Today) -- Enhanced treatment of atopic dermatitis with topical corticosteroids significantly reduced hen's egg allergy compared with conventional reactive treatment in infants, but also resulted in adverse effects on growth, a randomized... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 29, 2023 Category: Allergy & Immunology Source Type: news
New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Asthma, Eczema Tied to Osteoarthritis Risk
(MedPage Today) -- Individuals with a history of atopic disease, such as asthma and eczema (a.k.a. atopic dermatitis), are at significantly increased risk for developing osteoarthritis (OA), analysis of medical insurance claims indicated.
With... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 29, 2023 Category: Allergy & Immunology Source Type: news
Another JAK Inhibitor Shows Efficacy for Atopic Dermatitis Another JAK Inhibitor Shows Efficacy for Atopic Dermatitis
A novel JAK inhibitor being evaluated for a broad array of inflammatory diseases was associated with efficacy and safety for treating atopic dermatitis in a pivotal multinational phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
AAD: Risk for Skin Cancer Higher for Adults With Atopic Dermatitis
MONDAY, March 27, 2023 -- Adults with atopic dermatitis (AD) have an increased risk for developing melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), with significantly higher risks seen for moderate-to-severe versus mild AD,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 27, 2023 Category: Pharmaceuticals Source Type: news
Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor
(MedPage Today) -- NEW ORLEANS -- A novel lower-concentration topical formulation of the PDE4 inhibitor roflumilast produced rapid improvement in mild to moderate atopic dermatitis (AD) in children and adults, two randomized, vehicle-controlled... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 20, 2023 Category: Pediatrics Source Type: news
New Drug, Lebrikizumab, Could Be Treatment Option for People With Eczema
MONDAY, March 20, 2023 -- Patients could soon have access to a new injectable drug to treat atopic dermatitis, the most common form of eczema.
The drug, lebrikizumab, proved effective in teenagers and adults in two clinical trials just published in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2023 Category: General Medicine Source Type: news
Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis
THURSDAY, March 16, 2023 -- For adults and adolescents with moderate-to-severe atopic dermatitis, 16 weeks of lebrikizumab is effective, according to a study published online March 15 in the New England Journal of Medicine.
Jonathan I. Silverberg,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 16, 2023 Category: Pharmaceuticals Source Type: news
Mepitel Film for Radiation Dermatitis: It Works, so Why Isn't it Used? Mepitel Film for Radiation Dermatitis: It Works, so Why Isn't it Used?
Results from a phase 3 trial show that applying the silicone-based film before radiotherapy can reduce the incidence of radiation dermatitis, so why isn ' t it being used?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Dietary Triggers for Atopic Dermatitis in Children Dietary Triggers for Atopic Dermatitis in Children
While food allergies are often suspected of being the cause of atopic dermatitis in children, true true food-triggered AD is surprisingly rare, as discussed in this paper.Cutis (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 1, 2023 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
